DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID)

DCF Advisers LLC grew its holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) by 111.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,750 shares of the company’s stock after purchasing an additional 22,020 shares during the period. DCF Advisers LLC owned about 0.06% of Ovid Therapeutics worth $32,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of OVID. Vestal Point Capital LP bought a new position in shares of Ovid Therapeutics in the fourth quarter worth about $275,000. Assenagon Asset Management S.A. grew its stake in Ovid Therapeutics by 45.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 114,265 shares of the company’s stock worth $349,000 after acquiring an additional 35,786 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Ovid Therapeutics by 66.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 13,579 shares of the company’s stock worth $41,000 after acquiring an additional 5,401 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Ovid Therapeutics by 74.7% during the first quarter. BNP Paribas Financial Markets now owns 32,162 shares of the company’s stock valued at $98,000 after acquiring an additional 13,756 shares in the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of Ovid Therapeutics by 8.1% in the first quarter. Empowered Funds LLC now owns 128,070 shares of the company’s stock valued at $391,000 after purchasing an additional 9,625 shares during the period. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on OVID shares. Oppenheimer downgraded Ovid Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 18th. B. Riley cut their price target on Ovid Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. Citigroup lowered their price objective on shares of Ovid Therapeutics from $3.50 to $1.20 and set a “neutral” rating for the company in a research note on Tuesday, June 18th. William Blair raised shares of Ovid Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a report on Monday, August 19th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $4.70.

Ovid Therapeutics Stock Performance

Shares of Ovid Therapeutics stock opened at $1.17 on Friday. The company has a market capitalization of $83.01 million, a PE ratio of -1.60 and a beta of 0.42. The company has a 50-day simple moving average of $1.07 and a two-hundred day simple moving average of $2.08. Ovid Therapeutics Inc. has a one year low of $0.68 and a one year high of $4.10. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.73 and a current ratio of 5.73.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.34. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.14 million. Ovid Therapeutics had a negative net margin of 5,237.15% and a negative return on equity of 33.40%. Research analysts expect that Ovid Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.